Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

logo-inverse

CLIENT'S NEWS
Domain Therapeutics
admin

Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology

Strasbourg, France – Montreal, Canada, June 28, 2022 – Domain Therapeutics, a biopharmaceutical company focusing on the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.

Read More »
2022-06-28
Wefight
admin

Launch of Vik Colorectal in Spain

We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!

Read More »
2022-06-18
Transcure
admin

TransCure bioServices is AAALAC Accredited

TransCure bioServices is proud to announce that our facility is now fully accredited by the AAALAC, a compelling achievement rewarding hard-work and dedication to the humane and responsible care and use of animals.

Read More »
2022-06-17

Acticor Biotech obtains “PRIME” status from the European Medicines Agency for glenzocimab in the treatment of stroke

Paris, France, July 21, 2022 – 7:00 PM CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.

Learn more

Subtle Medical Announces Partnership Expansion With Incepto

Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced they are expanding their partnership with Incepto, a leading platform of artificial intelligence solutions for radiology professionals in Europe, by offering their AI applications, SubtleMR and SubtlePET on Incepto’s platform.

Learn more

Latest Insights

Domain Therapeutics raises $42m Series A financing

2022-05-10

Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.

Wefight annouces its partnership with Kiplin

2022-05-18

We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!

Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery

2022-04-19

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration agreement with Domain Therapeutics S.A. (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM”), to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) in a metabolic disease area